MA60122B1 - Anticorps se liant à la protofibrille d'alpha-synucléine - Google Patents

Anticorps se liant à la protofibrille d'alpha-synucléine

Info

Publication number
MA60122B1
MA60122B1 MA60122A MA60122A MA60122B1 MA 60122 B1 MA60122 B1 MA 60122B1 MA 60122 A MA60122 A MA 60122A MA 60122 A MA60122 A MA 60122A MA 60122 B1 MA60122 B1 MA 60122B1
Authority
MA
Morocco
Prior art keywords
alpha
antibodies binding
synuclein
synuclein protofibril
ban0805
Prior art date
Application number
MA60122A
Other languages
English (en)
Inventor
Jessica SIGVARDSON
Eva NORDSTRÖM
Patrik NYGREN
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of MA60122B1 publication Critical patent/MA60122B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention est basée, en partie, sur la découverte d'anticorps qui ciblent sélectivement des agrégats d'α-synucléine humaine tels que des oligomères/protofibrilles, tels que BAN0805. Le BAN0805 a une tendance réduite à se lier à la cible monomère, l'α-synucléine, indésirable par comparaison avec l'anticorps monoclonal murin mAb47
MA60122A 2020-06-26 2021-06-25 Anticorps se liant à la protofibrille d'alpha-synucléine MA60122B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063044881P 2020-06-26 2020-06-26
US202063071150P 2020-08-27 2020-08-27
PCT/IB2021/000440 WO2021260434A1 (fr) 2020-06-26 2021-06-25 Anticorps se liant à la protofibrille d'a-synucléine
EP21765693.3A EP4172199B1 (fr) 2020-06-26 2021-06-25 Anticorps se liant à la protofibrille d'alpha-synucléine

Publications (1)

Publication Number Publication Date
MA60122B1 true MA60122B1 (fr) 2025-07-31

Family

ID=77627146

Family Applications (1)

Application Number Title Priority Date Filing Date
MA60122A MA60122B1 (fr) 2020-06-26 2021-06-25 Anticorps se liant à la protofibrille d'alpha-synucléine

Country Status (27)

Country Link
US (2) US11339212B2 (fr)
EP (2) EP4172199B1 (fr)
JP (2) JP7337959B2 (fr)
KR (1) KR20230027095A (fr)
CN (1) CN115803341A (fr)
AU (1) AU2021298222A1 (fr)
CA (1) CA3181207A1 (fr)
DK (1) DK4172199T3 (fr)
ES (1) ES3037420T3 (fr)
FI (1) FI4172199T3 (fr)
HR (1) HRP20250812T1 (fr)
HU (1) HUE072262T2 (fr)
IL (1) IL298584B2 (fr)
LT (1) LT4172199T (fr)
MA (1) MA60122B1 (fr)
MD (1) MD4172199T2 (fr)
MX (1) MX2022016005A (fr)
PH (1) PH12022552829A1 (fr)
PL (1) PL4172199T3 (fr)
PT (1) PT4172199T (fr)
RS (1) RS66984B1 (fr)
SI (1) SI4172199T1 (fr)
SM (1) SMT202500274T1 (fr)
TW (1) TWI879983B (fr)
UY (1) UY39295A (fr)
WO (1) WO2021260434A1 (fr)
ZA (1) ZA202211843B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4172199T3 (da) 2020-06-26 2025-08-18 Bioarctic Ab Alfa-synuklein-protofibril-bindende antistoffer
WO2026068513A1 (fr) 2024-09-24 2026-04-02 Bioarctic Ab Molécule de liaison bispécifique

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007301A1 (fr) * 1993-09-07 1995-03-16 Smithkline Beecham Corporation Anticorps recombines contre l'il4 utiles dans le traitement des affections induites par l'il4
DE69928809T2 (de) 1998-07-03 2006-08-31 Innogenetics N.V. Differentielle diagnose von neurodegeneration
CA2414772C (fr) 2000-07-07 2011-06-28 Jan Naslund Prevention et traitement de la maladie d'alzheimer
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (fr) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Anticorps a l'alpha-synucleine
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1989330A4 (fr) 2006-01-31 2009-10-21 Elan Pharm Inc Alpha-synucléine kinase
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CN102317316B (zh) * 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
SI2723379T1 (sl) * 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015097536A2 (fr) * 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anticorps et fragments anti-vista
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
DK4172199T3 (da) 2020-06-26 2025-08-18 Bioarctic Ab Alfa-synuklein-protofibril-bindende antistoffer

Also Published As

Publication number Publication date
KR20230027095A (ko) 2023-02-27
HUE072262T2 (hu) 2025-11-28
TWI879983B (zh) 2025-04-11
SI4172199T1 (sl) 2025-08-29
US20210403542A1 (en) 2021-12-30
FI4172199T3 (fi) 2025-08-12
EP4570315A3 (fr) 2025-09-17
MD4172199T2 (ro) 2025-09-30
IL298584B2 (en) 2024-10-01
TW202212357A (zh) 2022-04-01
WO2021260434A1 (fr) 2021-12-30
HRP20250812T1 (hr) 2025-09-12
LT4172199T (lt) 2025-07-10
IL298584A (en) 2023-01-01
MX2022016005A (es) 2023-02-02
PL4172199T3 (pl) 2025-09-22
ES3037420T3 (en) 2025-10-01
EP4172199B1 (fr) 2025-05-14
JP2023525174A (ja) 2023-06-15
JP2023159299A (ja) 2023-10-31
US20230080536A1 (en) 2023-03-16
ZA202211843B (en) 2024-02-28
US11339212B2 (en) 2022-05-24
PT4172199T (pt) 2025-08-11
DK4172199T3 (da) 2025-08-18
UY39295A (es) 2022-01-31
PH12022552829A1 (en) 2023-06-14
JP7337959B2 (ja) 2023-09-04
CN115803341A (zh) 2023-03-14
EP4570315A2 (fr) 2025-06-18
IL298584B1 (en) 2024-06-01
AU2021298222A1 (en) 2022-12-15
SMT202500274T1 (it) 2025-09-12
EP4172199A1 (fr) 2023-05-03
CA3181207A1 (fr) 2021-12-30
RS66984B1 (sr) 2025-07-31

Similar Documents

Publication Publication Date Title
MA46731A (fr) Anticorps anti-tmprss2 et fragments de liaison à l'antigène
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
ZA202107047B (en) Heterodimeric antibodies that bind enpp3 and cd3
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
MA60122B1 (fr) Anticorps se liant à la protofibrille d'alpha-synucléine
PE20220708A1 (es) Anticuerpos anti-cd73
ATE394673T1 (de) Selbstanordnende moleküle
MX2022006881A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
DE60327205D1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
NZ604415A (en) Anti-il-23 heterodimer specific antibodies
PE20141162A1 (es) Anticuerpos anti-il-23
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
ATE550353T1 (de) Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
MX2024009860A (es) Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
ZA202403273B (en) Anti-lag3 bispecific antibody, pharmaceutical composition and use
MX2023007023A (es) Proteinas de inmunoglobulina que se unen a agonistas de npr1.
BR112022004603A2 (pt) Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
WO2022159839A8 (fr) Anticorps monoclonaux contre les coronavirus et leurs utilisations
WO2018231339A3 (fr) Anticorps anti-pd-1 tyrosine phosphorylé et ses utilisations
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
WO2023196658A3 (fr) Compositions d'anticorps et méthodes d'optimisation